Orion Corporation DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Orion Corporation Converts 337,000 A Shares to B Shares

20 Aug 2025

// GLOBENEWSWIRE

Flexilev® in OraFID® Gets Approval in All Nordic Countries

13 Aug 2025

// PR NEWSWIRE

Orion Corp: Manager Transactions - Juhani Kankaanpää

08 Aug 2025

// GLOBENEWSWIRE

DATA COMPILATION
#PharmaFlow

Contact Supplier

Website

Cell Therapy

Not Confirmed

Book a meeting

envelop Contact Supplier

DIGITAL CONTENT

2 Data Compilation #PharmaFlow, 330 News #PharmaBuzz

media
2 Data Compilation #PharmaFlow
330 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

4 All APIs, 4 VMF

4 All APIs
4 VMF

DEVELOPMENTS

144 Drugs in Development

144 Drugs in Development

FINISHED DOSAGE FORMULATIONS

588 FDF Dossiers, 7 FDA Orange Book, 534 Europe, 47 Canada

588 FDF Dossiers
7 FDA Orange Book
534 Europe
47 Canada

INSPECTIONS & REGISTRATIONS

7 FDA, 2 GDUFA

inspections
7 FDA
2 GDUFA

About

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's customers are mainly healthcare service providers and professionals such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics, etc.

CPhI WW FrankfurtCPhI WW Frankfurt

Industry Trade Show

Booth #5.1A92

28-30 October, 2025

Frankfurt
Contract PharmaContract Pharma

Industry Trade Show

Exhibiting

18-19 September, 2025

Hyatt Regency New Brunswick, NJ
Bio-EuropeBio-Europe

Industry Trade Show

Attending

03-05 November, 2025

Vienna, Austria

CONTACT DETAILS

Click the arrow to open the dropdown

Country

Finland

Address

Head officeOrion CorporationOrionintie 1A, FI-02200 Espoo, FinlandP.O.Box 65, ...

Telephone

+358 10 4261

fermionSales@fermion.fi

Website

https://www.orion.fi/en/

https://www.linkedin.com/company/orion-corporation/

YouTube

Digital content

Explore the latest content creation from this company

DATA COMPILATION #PharmaFlow

CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord). Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation.

Impressions: 8162

Chinese FDA-registered generic facilities gain steam, India maintains lead with 396 facilities

Every year, the US Food and Drug Administration (FDA) publishes the user fee amounts it will collect from manufacturers of pharmaceuticals, generic drugs, biosimilars and medical devices in the coming financial year. The fee for fiscal year 2025 under the Generic Drug User Fee Act (GDUFA) was published on July 31, 2024.The GDUFA, established in 2012, authorizes FDA to assess and collect fees from drug manufacturers to expedite the delivery of safe, high-quality, and affordable generic drugs to the American public.The FDA’s facility payments list under GDUFA reveals that as of November 14, 2024, 1,397 facilities had paid their registration fees for financial year 2025. Of these facilities, 707 or 50.6 percent are active pharmaceutical ingredients (API) facilities, 405 or 29 percent are finished dosage forms (FDF) facilities, 69 (4.9 percent) are facilities that produce both APIs and FDFs, and 216 (15.5 percent) are contract manufacturing services (CMO) sites.Teva Pharmaceuticals, with 29 facility registrations, led the list of companies, followed by Aurobindo Pharma, Sun Pharma, and Dr. Reddy's Laboratories. Fiscal year Facility Registrations 2016 1,425 2017 1,442 2018 1,269 2019 1,286 2020 1,300 2021 1,340 2022 1,385 2023 1,394 2024 1,447 2025 1,397 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available)India continues to lead with 396 facilities, US and China follow India maintains its dominance in total facility registrations with the FDA, registering 396 facilities for FY2025. This includes 214 API facilities, 135 FDF facilities, 21 facilities engaged in both API and FDF activities, and 26 CMO facilities.The United States holds the second position with 328 facilities, while China strengthened its third position with 197 facilities.With 214 API facilities, India continues to have the largest share of API manufacturing sites, outmatching the combined total of China (128) and the US (83), which together account for 211 facilities. Among European manufacturers, Italy leads with 59 API manufacturing sites, followed by Spain (30) and Germany (25).The US has maintained its lead in FDF facilities with 143 sites, followed closely by India with 135 sites and China with 45 sites. Country API FDF Both CMO Total India 214 135 21 26 396 US 83 143 13 89 328 China 128 45 12 12 197 Italy 59 3 2 19 83 Germany 25 4 1 15 45 Spain 30 9 1 4 44 Canada 7 17 13 37 Taiwan 9 6 5 4 24 Switzerland 15 4 4 23 France 16 6 22 Japan 18 1 19 United Kingdom 12 1 2 15 Mexico 9 1 1 11 Ireland 5 5 1 11 Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) GDUFA III user fee rates increase across categories for FY25The GDUFA, which was reauthorized on September 30, 2022 (as GDUFA III), continues with provisions that will last until September 30, 2027. In July 2024, the FDA published updated user fee rates for FY2025.The facility fees have seen increases across all categories. API facility fees increased by 3 percent for domestic sites (to US$ 41,580) and 2 percent for foreign sites (to US$ 56,580). FDF facility fees rose by 5 percent for both domestic (to US$ 231,952) and foreign sites (to US$ 246,952). CMO facility fees increased by 5 percent for domestic sites (to US$ 55,668) and 4 percent for foreign sites (to US$ 70,668).Additionally, the fee for large-, medium- and small-sized drug applicants has increased by over 9 percent, compared to the 7 percent increase seen in 2023. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) China leads new facility registrations as FDA records 41 new units in FY25Out of the total 1,397 facilities registered for FY2025, 41 were new registrations (going by Facility FDA Establishment Identifier numbers). China led the way with 13 new facilities, followed closely by India with 11 new facilities, while the US secured the third position with eight new facilities.The new registrations included 15 API facilities, 13 CMO facilities, 12 FDF facilities, and one facility engaged in both API and FDF activities. Chinese companies dominated the new FDF registrations with six facilities: Chengdu Shuode Pharma, Chengdu Suncadia Medicine, Cipla (Jiangsu), GE Healthcare (Shanghai), Luoxin Aurovitas Pharma (Chengdu), and Zhejiang Xianju Pharma.India added two new FDF facilities through Eugia Steriles and Zydus Pharma. Malaysia registered two FDF facilities through Novugen Pharma and Novugen Oncology, while Turkey’s Insud Pharma subsidiary Exeltis and US’ RK Pharma registered one FDF facility each.The 13 new CMO facilities included, Acme Generics, Emcure, Esjay Pharma, Fordoz Pharma, Fourrts Laboratories, Laboratoires KABS, PharmaMax, Quality Packaging Specialists International, Ritsa Pharma, Shanghai Aucyun Pharma, Sichuan Huiyu Pharma, Taejoon Pharm, and Tubilux Pharma.In the API category, the 15 new registrations included Acharya Chemicals, Hainan Poly Pharma, CBL Patras, EUROAPI, Hybio Pharma, Medilux Laboratories, Metrochem API, Purolite, Chengdu Easton Biopharma, Sionc Pharma, Smithfield Bioscience, Xttrium Laboratories, Zhejiang Hengkang Pharma, Moehs Iberica and Shilpa Pharma. Armstrong Pharmaceuticals registered the sole facility for both APIs and FDFs.So far, 92 facilities have not renewed their registration. Among these was a facility owned by Sandoz subsidiary Eon Labs in Wilson, North Carolina (US), which is permanently closed. In fact, the geographical distribution of non-renewals shows that 30 facilities were from the US, while India and China accounted for 14 and nine non-renewals respectively. Generic Drug Facilities Registered with the US FDA for FY2025 (Free Excel Available) Our viewThe FY 2025 GDUFA facility registration data indicates a continued strong presence of Indian manufacturers in the US generic drug market, particularly in API production. However, China's leadership in new facility registrations, especially in FDF manufacturing, suggests that the global generic drug supply chain landscape may evolve considerably in the coming years.

Impressions: 14312

NEWS #PharmaBuzz

Orion Corporation Converts 337,000 A Shares to B Shares

20 Aug 2025

// GLOBENEWSWIRE

Flexilev® in OraFID® Gets Approval in All Nordic Countries

13 Aug 2025

// PR NEWSWIRE

Orion Corp: Manager Transactions - Juhani Kankaanpää

08 Aug 2025

// GLOBENEWSWIRE

Orion Corporation: Managers' transactions – Satu Ahomäki

04 Aug 2025

// GLOBENEWSWIRE

EU Approves Darolutamide for Advanced Prostate Cancer

21 Jul 2025

// PRESS RELEASE

Orion Group Half-Year Financial Report January–June 2025

18 Jul 2025

// PRESS RELEASE

ALL APIs

Click the button for full data set

01

Pyrantel Pamoate

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCI Medicinal Chemistry

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF

Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

MANUFACTURING OPERATIONS

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCI Medicinal Chemistry

Not Confirmed

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF

Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

MANUFACTURING OPERATIONS

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCI Medicinal Chemistry

Not Confirmed

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF

Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

MANUFACTURING OPERATIONS

Finland

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

SCI Medicinal Chemistry

Not Confirmed

USDMF CEP/COS JDMF EU-WC NDC KDMF VMF

Others AUDIT

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

VMF

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

Europe

01

Brand Name : Allopurinol Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Sweden

allopurinol

Orion Corporation

Dosage Form : TABLET

Dosage Strength : 300 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

02

Brand Name : Allopurinol Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Sweden

allopurinol

Orion Corporation

Dosage Form : TABLET

Dosage Strength : 100 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

03

Brand Name : Allopurinol Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Norway

Allopurinol

Orion Corporation

Dosage Form : Antic-calc Tablet

Dosage Strength : 100 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

04

Brand Name : Allopurinol Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Norway

Allopurinol

Orion Corporation

Dosage Form : Antic-calc Tablet

Dosage Strength : 300 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

05

Brand Name : Alprazolam Orion

Finland

NASP

Not Confirmed

Regulatory Info :

Registration Country : Sweden

alprazolam

Orion Corporation

Dosage Form : TABLET

Dosage Strength : 0.25 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

06

Brand Name : Alprazolam Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Sweden

alprazolam

Orion Corporation

Dosage Form : TABLET

Dosage Strength : 0.5 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

07

Brand Name : Alprazolam Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Sweden

alprazolam

Orion Corporation

Dosage Form : TABLET

Dosage Strength : 1 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

08

Brand Name : Alprazolam Orion

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Sweden

alprazolam

Orion Corporation

Dosage Form : TABLET

Dosage Strength : 2 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

09

Brand Name : Penomax

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Norway

Amdinocillin Pivoxil

Orion Corporation

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 200 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

10

Brand Name : Penomax

Finland

SCI Medicinal Chemistry

Not Confirmed

Regulatory Info :

Registration Country : Norway

Amdinocillin Pivoxil

Orion Corporation

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 200 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

Product
Web Link

Stock Recap
#PipelineProspector

Market
Place

Only 10 entries up to this point, click to access all

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Inspections and registrations

Check the inspections & registration from this company

FDA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

GDUFA

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Contact Orion Corporation and get a quotation

Orion Corporation is a supplier offers 2 products (APIs, Excipients or Intermediates).

Find a price of Pyrantel Pamoate bulk offered by Orion Corporation

Find a price of MANUFACTURING OPERATIONS bulk offered by Orion Corporation

Company profile for Orion Corporation